Effects of a whey protein supplementation on intrahepatocellular lipids in obese female patients.

Détails

ID Serval
serval:BIB_3BA27D1EE4D4
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Effects of a whey protein supplementation on intrahepatocellular lipids in obese female patients.
Périodique
Clinical Nutrition
Auteur⸱e⸱s
Bortolotti M., Maiolo E., Corazza M., Van Dijke E., Schneiter P., Boss A., Carrel G., Giusti V.,  K.A., Quo Chong D.G., Buehler T., Kreis R., Boesch C., Tappy L.
ISSN
1532-1983 (Electronic)
ISSN-L
0261-5614
Statut éditorial
Publié
Date de publication
2011
Volume
30
Numéro
4
Pages
494-498
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
Background & aims: High protein diets have been shown to improve hepatic steatosis in rodent models and in high-fat fed humans. We therefore evaluated the effects of a protein supplementation on intrahepatocellular lipids (IHCL), and fasting plasma triglycerides in obese non diabetic women.Methods: Eleven obese women received a 60 g/day whey protein supplement (WPS) for 4-weeks, while otherwise nourished on a spontaneous diet, IHCL concentrations, visceral body fat, total liver volume (MR), fasting total-triglyceride and cholesterol concentrations, glucose tolerance (standard 75 g OGTT), insulin sensitivity (HOMA IS index), creatinine clearance, blood pressure and body composition (bio-impedance analysis) were assessed before and after 4-week WPS.Results: IHCL were positively correlated with visceral fat and total liver volume at inclusion. WPS decreased significantly IHCL by 20.8 +/- 7.7%, fasting total TG by 15 +/- 6.9%, and total cholesterol by 7.3 +/- 2.7%. WPS slightly increased fat free mass from 54.8 +/- 2.2 kg to 56.7 +/- 2.5 kg, p = 0.005). Visceral fat, total liver volume, glucose tolerance, creatinine clearance and insulin sensitivity were not changed.Conclusions: WPS improves hepatic steatosis and plasma lipid profiles in obese non diabetic patients, without adverse effects on glucose tolerance or creatinine clearance. Trial Number: NCT00870077, ClinicalTrials.gov (C) 2011 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
Pubmed
Web of science
Création de la notice
09/09/2011 10:44
Dernière modification de la notice
20/08/2019 14:31
Données d'usage